Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02605304 · ClinicalTrials.gov registry record · Phase 2
12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
A Phase 2 study, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02605304 is a Phase 2 study that was terminated before completion, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 7 participants.
The verdict
NCT02605304, a Phase 2 study, was terminated before completion, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
People who are infected with Hepatitis C Virus (HCV) have a great chance of being cured of the infection when they are treated with sofosbuvir. However, in some instances, treatment with sofosbuvir-containing therapy does not work. It is not known if people respond to retreatment with sofosbuvir, after it did not work the first time. There is an important need to understand retreatment options in those instances. This clinical trial was done to study the response to two different regimens, ledipasvir/sofosbuvir and ledipasvir/sofosbuvir with ribavirin, and to see if they are safe and well-tolerated in HCV-infected persons whose previous treatment with sofosbuvir had failed.
Interventions
- DRUG Ribavirin
- DRUG Ledipasvir/sofosbuvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-02-17 |
| Est. Completion | 2017-03-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02605304
The ClinicalTrials.gov registry entry for NCT02605304 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ribavirin is the first listed.
NCT02605304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02605304 about?
NCT02605304 is a clinical study titled "12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF". People who are infected with Hepatitis C Virus (HCV) have a great chance of being cured of the infection when they are treated with sofosbuvir. However, in some instances, treatment with sofosbuvir-containing therapy does not work. It is not known if people respond to retreatment with sofosbuvir, af...
What is the current status of trial NCT02605304?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2016-02-17. Estimated completion is 2017-03-20.
What interventions are being tested in trial NCT02605304?
The interventions under investigation include: Ribavirin (DRUG), Ledipasvir/sofosbuvir (DRUG).
Who is sponsoring clinical trial NCT02605304?
This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.